UBS has downgraded Sanofi to “neutral” due to concerns over its weak pipeline and the risk associated with its blockbuster drug Dupixent. This decision comes after the pharmaceutical company reported disappointing clinical trial results for a potential new cancer treatment. Sanofi’s stock has dropped by 3% following the news.

Read more at Investing.com: UBS downgrades Sanofi to “neutral” on weak pipeline and Dupixent risk